Low‐Dose Valganciclovir for Primary Cytomegalovirus Prophylaxis After Heart Transplant: A 10‐Year Experience
This is the largest report of LD VGCV use in HTR. Despite reduced VGCV exposure, HTR remain at high risk for cytopenias. Regardless of potential risk factors, including a high prevalence of overweight BMI and adequate renal function, LD VGCV was associated with expected rates of BT CMV and CMV resistance, suggesting LD VGCV could be considered in HTR. Identification of CMV end-organ disease and GCV resistance suggests that LD VGCV could be considered cautiously in CMV D+/R- HTR.
Authors
- Kennedy Concannon (ORCID: https://orcid.org/0009-0008-2803-9704)
- Emily Sartain (ORCID: https://orcid.org/0000-0002-4667-8074)
- Rebecca Swayngim (ORCID: https://orcid.org/0000-0002-4739-3484)
- Robert L Page nd (ORCID: https://orcid.org/0000-0003-2390-2392)
- Amrut V. Ambardekar (ORCID: https://orcid.org/0000-0003-3503-4203)
- Chia‐Yu Chiu (ORCID: https://orcid.org/0000-0002-5241-3435)
- Kelly E. Schoeppler (ORCID: https://orcid.org/0000-0002-7058-6831)
Institutions
- University of Colorado Hospital (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Montana (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1111/ctr.70408
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00